Ergomed plc Director/PDMR Shareholding (0319C)

TIDMERGO

RNS Number : 0319C

Ergomed plc

13 June 2019

Ergomed Plc

("Ergomed" or the "Company")

PDMR Dealing

Ergomed, a company focused on providing specialised services to the pharmaceutical industry, announces that on 12 June 2019, Richard Barfield, Chief Financial Officer of the Company, purchased 64,000 ordinary shares of 1 pence each in the Company ("Share(s)") at a price of 270 pence per Share (the "Purchase").

Following the Purchase, Richard Barfield's holding in the Company is 100,000 Shares (representing 0.21 per cent. of the Company's issued share capital).

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                     Richard Barfield 
      ---------------------------------------  ------------------------------------------------ 
 2     Reason for the notification 
      ----------------------------------------------------------------------------------------- 
 a)    Position/status                          Chief Financial Officer 
      ---------------------------------------  ------------------------------------------------ 
 b)    Initial notification                     Initial Notification 
        /Amendment 
      ---------------------------------------  ------------------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------------------------- 
 a)    Name                                     Ergomed Plc 
      ---------------------------------------  ------------------------------------------------ 
 b)    Legal Entity                             213800BVS8I9VMC1AP84 
        Identifier 
      ---------------------------------------  ------------------------------------------------ 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ----------------------------------------------------------------------------------------- 
 a)    Description of                           Ordinary shares of 1 pence each 
        the financial 
        instrument, type 
        of instrument                            GB00BN7ZCY67 
 
        Identification 
        code 
      ---------------------------------------  ------------------------------------------------ 
 b)    Nature of the                            Purchase of Shares 
        transaction 
      ---------------------------------------  ------------------------------------------------ 
 c)    Currency                                 GBP 
      ---------------------------------------  ------------------------------------------------ 
 d)    Price(s) and                                     Price(s)                Volume(s) 
        volume(s) 
      ---------------------------------------  -------------------------  --------------------- 
                                 270 pence                                        64,000 
  ----------------------------------------------------------------------  --------------------- 
 
 e)    Aggregated information                   Volume: 64,000 ordinary shares of 1 pence 
        - Aggregated                             each, purchase price of 270 pence per share 
        volume                                   Aggregated: GBP172,800.00 
        - Price 
        - Aggregated 
        total 
      ---------------------------------------  ------------------------------------------------ 
 f)    Date of the transaction                  12 June 2019 
      ---------------------------------------  ------------------------------------------------ 
 g)    Place of the                             London Stock Exchange, AIM 
        transaction 
      ---------------------------------------  ------------------------------------------------ 
 

Enquiries:

 
 Ergomed plc                                       Tel: [phone] 
                                                                     975 
 Miroslav Reljanović (Executive 
  Chairman) 
 
 
 Numis Securities Limited                           Tel: [phone] 
                                                                    1000 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications                 Tel: [phone] 
  - for UK enquiries                                                5700 
 Chris Gardner / Mary-Jane Elliott           [e-mail] 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European           Tel: [phone] 
  enquiries 
 Anne Hennecke 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKMGMVNZGGLZM

(END) Dow Jones Newswires

June 13, 2019 02:01 ET (06:01 GMT)